Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study

T Nakano, K Kuribayashi, M Kondo… - Asia‐Pacific Journal …, 2021 - Wiley Online Library
Aims Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …
被引用次数：3 相关文章

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study

T Nakano, K Kuribayashi, M Kondo, M Morise… - Asia‐Pacific Journal of …, 2021 - infona.pl
Aims Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.

T Nakano, K Kuribayashi, M Kondo… - Asia-pacific Journal of …, 2020 - europepmc.org
Aims Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study

T Nakano, K Kuribayashi, M Kondo… - Asia-Pacific Journal …, 2021 - pure.fujita-hu.ac.jp
Aims: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …
[HTML] nih.gov

[HTML][HTML] Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study

T Nakano, K Kuribayashi, M Kondo… - Asia-Pacific Journal …, 2021 - ncbi.nlm.nih.gov
Aims Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study

T Nakano, K Kuribayashi, M Kondo… - Asia-Pacific journal …, 2021 - pubmed.ncbi.nlm.nih.gov
Aims Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study

T Nakano, K Kuribayashi, M Kondo… - Asia-Pacific Journal …, 2021 - pure.fujita-hu.ac.jp
Aims: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …